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CD4+ Cell Count, Viral Load, and Highly Active
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Background. To understand the concurrent effects of human immunodeﬁciency virus (HIV) infection, the
immune system, and antiretroviral therapy on body composition alterations, we examined annualized composition
changes in HIV-infected adults who were receiving stable antiretroviral therapy.
Methods. With use of data from the Nutrition For Healthy Living Study, we performed multivariate analyses
using longitudinal models to evaluate the relationship of CD4+ cell count, viral load, and highly active antiretroviral
therapy (HAART) or antiretroviral therapy (ART) with changes in trunk and extremity composition for 110 men
and 42 women who provided data relating to 194 study intervals (i.e., intervals of time between 2 assessment visits).
Of these intervals, 165 involved HAART use (89.7% involved protease inhibitor–based regimens), and 29 did not
involve HAART use. Patients receiving HAART or ART (who had continuous use during the interval) were compared
with HAART- or ART-naive subjects.
Results. The median length of intervals between visits was 12.9 months (interquartile range, 12.1–17.6 months).
In models adjusted for HAART or ART use, baseline CD4+ cell count was positively associated with increased trunk
fat (mean increase per year, 2.3% per 100 cells/mm3; 95% conﬁdence interval [CI], 0.7%–3.9%]) and, in men, with
increased extremity fat (mean increase per year, 1.8% per 100 cells/mm3; 95% CI, 0.6%–3.0%). Increase in CD4+ cell
count predicted increased extremity lean mass (mean increase per year, 0.6% per 100 cells/mm3; 95% CI, 0.05%–
1.1%). Higher baseline viral load predicted fat loss (trunk fat loss per year, �5.0% per log10 copies/mL; 95% CI,
�9.4% to �0.7%; extremity fat loss per year, �3.4% per log10 copies/mL; 95% CI, �6.1% to �0.6%), as did
zidovudine use (trunk fat loss per year, �10.8%; 95% CI, �20.4% to �1.4%; extremity fat loss per year, �4.9%;
95% CI, �9.8% to �0.01%). HAART use independently predicted decreased bone mineral content (extremity bone
mineral content loss per year, �1.6%; 95% CI, �3.1% to �0.08%) but did not predict changes in fat or lean mass.
Receipt of protease inhibitor–based HAART predicted a �1.9% decrease in extremity bone mineral content per year
(95% CI, �3.6% to �0.2%), and zidovudine use predicted a �2.6% decrease in trunk bone mineral content per
year (95% CI, �4.4% to �0.8%).
Conclusions. Baseline viral load, CD4+ cell count, and change in CD4+ cell count predicted alterations in
trunk fat, extremity fat, and lean mass. HAART use and zidovudine use were associated with bone loss, and
zidovudine use was associated with fat loss, but HAART use was not associated with fat mass changes.
The complex array of morphologic changes experienced
by many HIV-infected individuals continues to puzzle
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the medical and scientiﬁc community. Common
changes have been reported to involve fat mass (FM),
lean mass (LM), and bone mass (BM) in a variety of
patterns and combinations [1, 2]. A cross-sectional,
multicenter study (Fat Redistribution and Metabolic
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Change in HIV Infection Study) comparing HIV-infected per
sons with healthy control subjects using MRI and dual–energy
x–ray absorptiometry (DEXA) suggests that central fat accu
mulation and peripheral fat atrophy occur independently [3].
Body mass index and percentage of body fat have been im
plicated in changes in FM [4]. Recent cross-sectional and lon
gitudinal studies report that lean mass may be increased in
persons receiving HAART [5–7], whereas other studies have
not found such an association [8, 9]. A drug initiation study
found that some body composition beneﬁts that occurred after
initiating antiretroviral therapy were transient [6]. DEXA ﬁnd
ings suggest that bone density is low in many individuals who
are seropositive for HIV infection [10–12] and that osteopenia
may be associated with fat mass abnormalities [13].
A number of difﬁculties exist in determining the cause of
body composition changes. One concern is the best method to
determine regional body composition. Speciﬁc medications or
antiretroviral therapy drug classes (e.g., protease inhibitors
[PIs], nucleoside reverse-transcriptase inhibitors [NRTIs], and
non-NRTIs [NNRTIs]) and antiretroviral therapy combinations
have been reported to affect body shape differently [5, 14–18],
and antiretroviral therapy regimens may change for a variety
of reasons. Predictors of body shape changes appear to include
baseline CD4+ cell count and viral load, as well as change in
CD4+ cell count and viral load [4, 6, 14, 19]. Although there
is no perfect marker of cumulative disease severity, CD4+ cell
count and viral RNA serve as useful surrogate markers of cur
rent disease activity and status. Data suggest that body shape
changes continue to occur over time [6, 14, 19].
To our knowledge, no published cohort studies have reported
the concurrent effects of medications, HIV disease markers,
and other cofactors on measures of regional FM, LM, and BM.
We longitudinally analyzed a medication-stable cohort of men
and women for independent predictors of regional body com
position alterations by DEXA.
SUBJECTS AND METHODS
Patients were participants in Nutrition for Healthy Living, an
observational cohort study initiated in 1995 to describe the
natural history of HIV disease and progression and to deter
mine the role of nutrition. Subjects �18 years old and with all
stages of disease were eligible. Recruitment was through ad
vertisements in local newspapers, radio, health clinics, and phy
sician networks in Boston, Massachusetts, and Providence,
Rhode Island. Exclusion criteria included pregnancy, severe di
arrhea, diabetes, thyroid disease, malignancies other than Ka
posi sarcoma, or poor English language ﬂuency at the time of
recruitment. Subjects made study visits at ∼6-month intervals
and completed surveys and 3-day food records and had blood
samples drawn at each visit. Since 1997, annual DEXA scans
have been conducted. Enrolled subjects continue to receive care

from their treating physicians. Additional details of the study
have been published elsewhere [8].
All subjects with a minimum of 2 DEXA scans conducted
at visits 11–24 months apart between June 1997 and June 2001
who had complete medication information were included in
this analysis (ﬁgure 1). For a subject to be included, medication
status had to be continuous 1 month prior to and throughout
the entire interval. If participants were involved in intervention
studies affecting nutrition or body composition, data for these
intervals and the 6 months after intervention were excluded.
Although 291 Nutrition for Healthy Living participants met
the 2-DEXA minimum in this time frame, only 110 men and
42 women met inclusion criteria for this analysis. Data available
on single individuals over multiple visits were used to create
multiple intervals for some of the subjects. These 152 individ
uals provided data for 194 intervals. Table 1 reports baseline
values for subject characteristics. Table 2 reports the body com
position characteristics at the start of each interval used in this
analysis. HAART users, deﬁned as those reporting continuous
use of HAART throughout the interval, were compared with
participants who were deemed to be HAART naive on the basis
of our data collection. Similarly, for speciﬁc medications and
medication classes, continuous users of each medication or
medication class were compared with those with no prior or
current use of the speciﬁed medication or medication class
reported. Duration of HAART or of antiretroviral therapy was
deﬁned as the number of months of previous cumulative use,
as determined by self-report at study entry, plus the months
to the start of an interval.

250 Persons with 2 DEXA scans

249 Persons with CD4+ cell count <1000 cells/mL

196 Persons with 2 DEXA scans 11-24 months apmt

132 Persons reporting
continuous
ART/HAART use &
no diet or body
composition
interventions

•

20 Persons reporting
ART-naive status & no diet
or body composition
interventions

,Ir

104 Persons with I interval
23 Persons with 2 intervals
5 Persons with 3 intervals

12 Persons with I interval
7 Persons with 2 intervals
I Persons with 3 intervals

Figure 1. Subject and interval selection. ART, antiretroviral therapy;
DEXA, dual-energy x-ray absorptiometry.
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Testing protocol. The protocol was approved by the Tufts
University Human Investigation Review Committee. Written
informed consent was obtained from all participants.
Transverse whole-body DEXA scans were obtained with a
single QDR2000 scanner (Hologic) in the array mode, per
formed by 1 of 3 validated technicians, and followed the pre
scribed Nutrition for Healthy Living protocol [5]. Whole-body
and regional analyses of soft tissues were performed using the
QDR2000 product software, version 7.10A (Hologic).
Individual antiretroviral medication use and duration of use
were recorded at each visit. Individual antiretroviral drugs were
classiﬁed by drug class (i.e., PI, NRTI, or NNRTI) and by drug
combinations as HAART or non-HAART. HAART regimens
included (1) �2 PIs (PI-based HAART), (2) �1 PI and �2
NRTIs (PI-based HAART), (3) �1 PI, �1 NRTI, and �1
NNRTI (mixed HAART), (4) �2 NRTIs and �1 NNRTI
(NNRTI-based HAART), or (5) �3 NRTIs (NRTI-based
HAART). An antiretroviral therapy user or HAART user was
deﬁned as someone reporting continuous antiretroviral therapy
or HAART use from the beginning of the interval through the
end of the interval. A subject was considered to be antiretroviral
therapy naive or HAART naive if there was no antiretroviral
therapy or HAART use in the 12 months before entry into the
Nutrition for Healthy Living study and none initiated by the
date of the ﬁnal DEXA.
History of AIDS diagnosis included a CD4+ cell count !200
cells/mm3 at the time of any study visit, self-reported occur
rence of any AIDS-deﬁning illness, or AIDS diagnosis before
or during participation in the Nutrition for Healthy Living
study. HIV RNA level was measured with the Roche Amplicor
Monitor RT-PCR assay (Roche Molecular Systems), with a
lower limit of detection of 400 copies/mL. Viral loads that were
undetectable using this assay were assigned the mean value of
200 copies/mL (i.e., 2.3 log10 copies/mL). CD4+ lymphocyte
counts were performed using a speciﬁc monoclonal antibody
and ﬂuorescence-activated, cell-sorted analysis.
Statistical analysis. Under the guidance of a research stat
istician, statistical analyses were performed using SAS software,
versions 8 and 9 (SAS). Subjects’ characteristics were tabulated
on the basis of the individual’s data at the baseline of their ﬁrst
interval, as well as from all included intervals. Binary charac
teristics were described by CD4+ cell count and by percentage
of nonmissing values. Differences between groups were tested
for signiﬁcance using the x2 test or, if there were !5 observations
in a cell, using the Fisher exact test. Continuous characteristics
were expressed as mean (SD) or, if the data were highly
skewed, as median (interquartile range). Differences between
groups were tested for signiﬁcance using the Student’s t test
or, if the data were highly skewed, the Wilcoxon rank sum test.
All statistical tests were 2-sided, and a was set at 5%.
The units of analysis were intervals, with an interval deﬁned
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as the time between 2 DEXA scans. To account for the variations
in time between the actual DEXA scan dates, data were pro
portionally adjusted to a 12-month period, and thereby created
annualized change. The dependent variable in regression mod
els was annualized percentage change in 6 body composition
measures; these included FM, LM, and bone mineral content
(BMC) in trunk and extremities (i.e., arms plus legs), as deﬁned
by DEXA. All independent variables (i.e., HAART use, HAART
class, antiretroviral therapy use, antiretroviral therapy class,
baseline CD4+ cell count, baseline viral load, age, sex, strength
training, smoking, and dietary intake) were measured at the
beginning of the interval, with the exception of annualized
change in CD4+ cell count and viral load, which were measured
over the interval. The within-person correlations were modeled
as ﬁrst-order autoregressive, to account for decreasing serial
correlation. All models were implemented with SAS Proc Mixed
(SAS) to allow for multiple intervals per person. All inferences
were conducted using the empirical SE to account for withinperson correlation [20]. This allows valid statistical inferences
to be made using data that come from 11 observation per
person.
Model diagnostics—including Cook’s distance, deletion of
outliers, residual plots, and normal probability plots—were
used to check for inﬂuential points, nonnormality, nonlinear
ities, and unequal variances. The stepwise restricted cubic spline
[21] was also used to check for nonlinearities.
Multivariate, longitudinal models separately assessing the ef
fect of CD4+ cell count and viral load on change in FM and
LM were adjusted for HAART use, age, sex, sex and HAART
interaction, energy intake !35 kcal/kg, and strength training.
Separate models assessing the effect of CD4+ cell count and
viral load on BMC were also adjusted for calcium intake less
than the dietary reference index value, vitamin D intake less
than the dietary reference index value, and smoking. Interac
tions of CD4+ cell count and viral load with sex were tested.
In separate multivariate, longitudinal models, we assessed
the effect of antiviral medications on body composition ad
justed for age, sex, baseline value and change in CD4+ cell count,
baseline value and change in viral load, energy intake !35 kcal/
kg, calcium intake less than the dietary reference index value,
vitamin D intake less than the dietary reference index value,
strength training, and smoking, as appropriate. Interactions of
medications with sex were tested.
RESULTS
Subjects. One hundred ten men and 42 women (a total of
152 subject) with a total of 194 intervals met inclusion criteria
for this analysis. Seventy-six percent of individuals provided 1
interval for analysis, 20% provided 2 intervals, and 4% provided
3 intervals. Table 1 presents the baseline assessments for the
participants. In subjects using HAART at baseline, the median

Table 1. Demographic and clinical characteristics of 152 HIV-infected adults enrolled in a longitudinal
study of body composition alterations at baseline visit for the ﬁrst study interval.
Variable

All subjects

Men

Women

No. (%) of subjects
Age, mean years  SD

152 (100)
42.7  6.9

110 (72)
43.5  6.8a

40.7  6.8

Body mass index, mean  SD

24.9  4.2

24.4  3.8b

Time since diagnosis, mean years  SD

7.4  3.6

7.4  3.6

Baseline CD4+ cell count, mean cells/mm3  SD
Annualized D in CD4+ cell count, mean cells/mm3  SD
Viral load, median log10 copies/mL (IQR)

430  227
�1  125

398  224
4  115

Annualized D in viral load, median log10 copies/mL (IQR)
AIDS diagnosis, no. (%) of subjects
Nonwhite ethnicity, no. (%) of subjects

42 (28)
26.4  4.8
7.3  3.7

b

522  211
�15  152

2.3 (2.3–3.8)

2.3 (2.3–3.9)

2.3 (2.3–3.1)

0 (�0.08 to 0.07)
82 (54.0)

0 (�0.08 to 0.09)
62 (56.4)

0 (0.0–0.0)
20 (47.6)

54 (35.5)

32 (29.1)b

Men who have sex with men, no. (%) of subjects

91 (59.9)

91 (82.7)

22 (52.4)
NA

History of injection drug use, no. (%) of subjects
Strength training in past week, no. (%) of subjects

15 (9.9)
37 (24.5)

8 (7.3)
34 (30.9)b

7 (16.7)

Current smoker, no. (%) of subjects

60 (40.0)

34 (31.2)b

26 (63.4)

NOTE.
range.
a
b

3 (7.3)

Student’s t test, x2 test, Wilcoxon rank sum test, or Fisher exact test were used as appropriate. IQR, interquartile

Statistically signiﬁcant difference between men and women (P ! .05).
Statistically signiﬁcant difference between men and women (P � .01).

time of continuous HAART use prior to the initial assessment
visit was 15.3 months (interquartile range, 7.0–26.7 months).
Median interval length was 12.9 months (interquartile range,
12.1–17.6 months). Of the 165 HAART-use intervals, 89.7% of
these involved regimens that were PI-based HAART; 29 were
non-HAART intervals.
Table 1 shows differences between men and women in the
cohort. On the basis of 3-day food record from their initial
visit, women were more likely to report insufﬁcient calcium
intake (69.1% did not meet the dietary reference index value,
compared with 34.6% of men; P ! .001) and insufﬁcient energy

intake (i.e., !35 kcal/kg of body weight) (69.1% of women vs.
30.9% of men; P ! .001) (data not shown). There were no statistically signiﬁcant differences by sex, except that women were
less likely to use HAART (76.2% vs. 90.9%; P p .02), more
likely to use non-HAART antiretroviral therapies (23.8% vs.
8.2%; P p .009) (data not shown), and had been receiving
HAART for a shorter duration (median duration, 6.8 vs. 15.2
months; P p .02) than were men. Baseline regional body com
position differed by sex (table 2); women had nearly double
the FM, two-thirds the LM, and less BMC than men (P !
.001 for all). No differences in annualized percentage change

Table 2. Baseline values and changes in regional body composition as assessed by dual-energy x-ray absorptiometry after the ﬁrst
study interval for 152 HIV-infected adults enrolled in a longitudinal study of body composition alterations.
Unadjusted baseline value,
median kg (IQR)
All subjects
(n p 152)

Men
(n p 110)

6.7 (4.1–10.4)
8.2 (4.6–11.6)

5.3 (3.8–7.6)b
6.8 (3.9–10.1)b

22.9 (18.8–26.4)
27.2 (23.5–30.8)

24.8 (22.0–27.5)
29.3 (26.5–32.0)b

Unadjusted annualized percentage
change, mean %  SD
Women
(n p 42)

All
(n p 152)

Men
(n p 110)

Women
(n p 42)

11.8 (8.7–16.3)

�3.9  20.0

�5.3  19.0

�0.31  22.4

11.2 (8.0–16.7)

4.4  35.1

4.1  30.9

5.2  44.8

Fat mass
Extremitiesa
Trunk
Lean body mass
Extremitiesa
Trunk
Bone mineral content
Extremitiesa
Trunk
NOTE.
a
b
c

1.3 (1.1–1.5)
0.65 (0.57–0.73)

b

1.4 (1.3–1.5)b
0.67 (0.58–0.75)b

16.0 (14.5–18.6)
21.0 (19.3–23.5)

0.33  5.6
0.96  4.1

�0.32  4.8
0.65  4.0

2.0  7.0
1.8  4.2

1.1 (1.0–1.2)

�0.71  4.03

�0.67  4.2

�0.82  3.7

0.57 (0.51–0.61)

�0.05  5.4

c

0.78  5.0

�2.3  5.9

Student’s t test, x2 test, Wilcoxon rank sum test, or Fisher exact test were used as appropriate. IQR, interquartile range.

Determined by the sum of arms plus legs to as deﬁned by dual-energy x-ray absorptiometry scan.
Statistically signiﬁcant difference between men and women (P ! .001).
Statistically signiﬁcant difference between men and women (P p .003).
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Figure 2. Effects of baseline value and change in CD4+ cell count and
viral load on fat mass, as assessed by dual-energy x-ray absorptiometry.
Data are expressed as the estimate of coefﬁcient (SE) for annualized
percentage change in fat mass from the beginning of an interval, adjusted
for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/
mL, respectively. Effects of baseline CD4+ cell count on extremity fat
mass are shown as separate bars for men and women because of sta
tistically signiﬁcant interaction; in men, the association is statistically
signiﬁcant (P p .005). Separate models were run for the 4 predictors of
interest: baseline CD4+ cell count, change in CD4+ cell count, baseline
viral load, and change in viral load. Each model was adjusted for HAART,
age, sex, and the combination of sex and HAART. In addition, the model
was adjusted for caloric intake !35 g/kg. The interaction between sex
and the predictor of interest was tested for each model. For extremity
fat mass, the interaction of sex and baseline CD4+ cell count was sta
tistically signiﬁcant (P p .04). Bars, standard error. *P ! .05.

in regional body composition were observed between men and
women, except for trunk BMC (P p .003) (table 2).
Predictors of Regional Body Composition Changes

Examining all 194 intervals (unadjusted interval data not
shown), the cohort experienced an average annual loss of 3.6%
of extremity FM (P p .011), with greater changes seen in men.
Increases in trunk FM were not signiﬁcant (P p .66). Trunk
LM (nonfat, nonbone mass) increased 0.9% per year (P p
.002), whereas extremity LM did not change. Small decreases
in extremity BMC were not statistically signiﬁcant. Women had
a statistically signiﬁcant annual loss of trunk BMC (mean un
adjusted change [SD] in women, �1.5%  5.6%; mean
unadjusted change [SD] in men, 0.94%  5.0%; P p .004
for sex interaction).
Baseline CD4+ cell count. Figures 2–4 illustrate adjusted
models examining CD4+ cell count and viral load effects on
regional changes. A positive linear relationship existed between
change in trunk fat and baseline CD4+ cell count, with a 2.3%
annualized mean increase in trunk fat per 100 CD4+ cells/mm3
(95% CI, 0.7%–3.9%; P p .006). The relationship between ex
tremity FM and baseline CD4+ cell count varied by sex (P p
.02 for sex interaction). Baseline CD4+ cell count predicted a
1.8% annualized mean increase in extremity FM per 100 CD4+
cells/mm3 in men only (95% CI, 0.6%–3.0%; P p .005); for
women, the association was not statistically signiﬁcant (P p
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.18). Baseline CD4+ cell count was not associated with changes
in LM or BMC.
Change in CD4+ cell count. Extremity LM increased with
changes in CD4+ cell count from baseline (mean increase per
year, 0.59% per 100 cells/mm3; 95% CI, 0.05%–1.1%; P p
.03).
Baseline viral load. Higher viral load at baseline predicted
a subsequent loss of extremity FM (mean decrease per year,
�3.4% per log10 copies/mL; 95% CI, �6.1% to �0.6%; P p
.02) and trunk FM (mean decrease per year, �5.0% per log10
copies/mL; 95% CI, �9.4% to �0.7%; P p .03).
Change in viral load. No association was found between
change in viral load and regional body composition changes.
Use of HAART or antiretroviral therapy. Table 3 shows
the association between use of speciﬁc antiretroviral therapy
and HAART regimens and body composition changes in ad
justed models. HAART use (found in 146 intervals) was as
sociated with a mean annual 1.6% loss of extremity BMC in
both sexes (95% CI, �3.1% to �0.08%; P p .04) and a mean
2.5% annualized LM increase in women (95% CI, 0.5%–4.6%;
P p .02) but with no other body composition changes.
Increased extremity LM (mean increase per year, 2.8%; 95%
CI, 0.1%–5.6%; P p .04) was associated with NNRTI-based
HAART regimens, but the number of intervals analyzed was
very small (16 of 169 intervals analyzed involved NNRTI-based
HAART regimens). PI-based HAART (used in 92 of 169 in
tervals) was associated with extremity BMC loss (mean decrease
per year, �1.9%; 95% CI, �3.6% to �0.2%; P p .03), but no
other HAART regimen had this association.
Zidovudine use (found in 60 of 103 intervals analyzed) was
associated with an annual decrease in extremity FM (mean
decrease per year, �4.9%; 95% CI, �9.8% to �0.01%; P p
.049) and trunk FM (mean decrease per year, �10.8%; 95%
CI, �20.4% to �1.4%; P p .02). Zalcitabine use was associated
with a decrease in trunk FM, and stavudine use was not. Use
of lamivudine (found in 117 of 127 intervals) was associated
with increased trunk LM (mean increase per year, 3.0%; 95%
CI, 0.1%–5.8%; P p .04). Although few individuals were re
ceiving didanosine (found in 27 of 137 intervals), use of the
agent was associated with a decrease in trunk LM (mean de
crease per year, �6.4%; 95% CI, �10.3% to �2.5%; P p
.002) in women only. Zidovudine use (found in 60 of 103
intervals) was associated with an annual decrease in trunk BMC
(mean decrease per year, �2.6%; 95% CI, �4.4% to �0.8%;
P p .005). The use of stavudine (found in 69 of 130 intervals)
was associated with an increase in trunk BMC (mean increase
per year, 2.0%; 95% CI, 0.4%–3.6%; P p .01).
Adjusted models found no effect on regional FM attributable
to use of any individual PI (table 3), but saquinavir use (found
in 28 of 91 intervals) and ritonavir use (found in 24 of 92
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Figure 3. Effects of baseline value and change in CD4+ cell count and viral load on lean mass, as assessed by dual-energy x-ray absorptiometry.
Data are expressed as the estimate of coefﬁcient (SE) for annualized percentage change in lean mass from the beginning of an interval, adjusted
for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/mL, respectively. Separate models were run for the 4 predictors of interest:
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the combination of sex and HAART. In addition, the model was adjusted for caloric intake !35 g/kg. The interaction between sex and the predictor
of interest was tested for each model. Bars, standard error. *P ! .05.

intervals) were each associated an annualized decrease in extremity LM (mean decrease per year, �1.4% [95% CI, �2.7%
to �0.7%] and �1.8% [95% CI, �3.2% to �0.4%], respectively; P p .04 and P p .01, respectively). Nelﬁnavir use (found
in 43 of 98 intervals) was associated with a 2.2% annualized
increase in extremity BMC (95% CI, 1.2%–3.2%; P ! .001).
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and the PIs ritonavir, indinavir, nelﬁnavir, and saquinavir and
was retained in these models. Cigarette smoking was associated
with annual decreases in BMC in the trunk (coefﬁcient range,

o Baseline viral load
• Change in viral load

-0.6
-0.8

-I

Figure 4. Effects of baseline value and change in CD4+ cell count and viral load on bone mineral content, as assessed by dual-energy x-ray
absorptiometry. Data are expressed as the estimate of coefﬁcient (SE) for annualized percentage change in bone mineral content from the beginning
of an interval, adjusted for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/mL, respectively. Separate models were run for the 4
predictors of interest: baseline CD4+ cell count, change in CD4+ cell count, baseline viral load, and change in viral load. Each model was adjusted for
HAART, age, sex, and the combination of sex and HAART. In addition, the model was adjusted for smoking status, vitamin D intake less than the
dietary reference intake value, and calcium intake less than the dietary reference intake value. The interaction between sex and the predictor of
interest was tested for each model. For the covariate of smoking status, there was a statistically signiﬁcant association with change in extremity
bone mineral content (P ! .001 for all) and trunk bone mineral content (P � .03). Bars, standard error. *P ! .05.
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Table 3.

Effect of antiretroviral therapy on annualized percentage change in regional body composition of HIV-infected adults receiving stable medication regimens.

Comparison group to by class

Intervals with
Total no.
continuous
of intervals regimen use
in the
to no. (%) of
analysis
total intervals

Annualized percentage change in regional body composition to estimate of coefﬁcient (95% CI)
Extremity
fat mass

Trunk
fat mass

Extremity
lean body mass

Trunk
lean body mass

a

Extremity
bone mineral
content

Trunk
bone mineral
content

By type of regimen
HAART vs. HAART naive

170

146 (85.9)

�2.2 (�8.8 to 4.3)

2.3 (�5.0 to 9.6)

0.03 (�1.8 to 1.9)

PI-based HAART vs. HAART naive

169

92 (54.4)

�2.0 (�9.5 to 5.4)

6.0 (�2.8 to 14.8)

0.30 (�1.7 to 2.3)

Mixed HAART vs. HAART naive

169

37 (21.9)

�1.4 (�8.8 to 6.0)

3.9 (�4.8 to 12.6)

NNRTI-based HAART vs. HAART naive

169

16 (9.5)

�5.4 (�15.1 to 4.2)

3.1 (�8.0 to 14.3)

Nelﬁnavir

98

43 (43.9)

�2.7 (�9.5 to 4.1)

Indinavir

87

31 (35.6)

Saquinavir

91

Ritonavir

Men: �0.98 (�2.0 to 0.2);
b
women: 2.5 (0.5–4.6)
0.83 (�0.6 to 2.3)

�1.5 (�3.7 to 0.7)

b

�1.6 (�3.1 to �0.08)

�0.10 (�1.9 to 1.7)

b

�0.09 (�2.1 to 1.9)

�1.9 (�3.6 to �0.2)

�0.78 (�2.2 to 0.7)

�1.4 (�3.2 to 0.4)

2.8 (0.1–5.6)

1.2 (�0.6 to 3.1)

�0.70 (�2.7 to 1.3)

0.87 (�7.5 to 9.3)

0.89 (�0.8 to 2.5)

0.56 (�0.8 to 1.9)

6.1 (�1.1 to 13.3)

4.9 (�4.1 to 13.8)

0.08 (�1.6 to 1.8)

�0.41 (�1.8 to 1.0)

28 (30.8)

�0.75 (�8.0 to 6.5)

�5.3 (�14.0 to 3.4)

�1.4 (�2.7 to �0.7)

92

24 (26.1)

�0.26 (�8.3 to 7.8)

�7.9 (�18.8 to 3.1)

�1.8 (�3.2 to �0.4)

127

117 (92.1)

�9.3 (�24.2 to 5.7)

b

0.78 (�1.2 to 2.8)
�1.6 (�4.5 to 1.2)

By drug
Speciﬁc PI-based HAART vs. all other
PI-based HAART naive
c

2.2 (1.2–3.2)

0.02 (�1.7 to 1.7)

�0.06 (�1.2 to 1.1)

0.26 (�1.8 to 2.4)

b

0.36 (�1.1 to 1.8)

�1.3 (�3.0 to 0.4)

0.43 (�1.6 to 2.4)

b

�0.26 (�1.5 to 1.0)

�1.6 (�3.4 to 0.1)

�0.67 (�3.0 to 1.6)

Speciﬁc NRTI-based HAART vs. all
other NRTI HAART
Lamivudine
Zidovudine

103

60 (58.3)

�18.5 (�41.5 to 4.4)
b

�4.9 (�9.8 to �0.01)

b

�10.8 (�20.1 to �1.4)

3.0 (0.10–5.8)

�0.67 (�3.5 to 2.2)

�0.92 (�4.7 to 2.8)

0.66 (�1.02 to 2.3)

0.88 (�0.39 to 2.1)

�1.2 (�2.4 to 0.10)

�2.6 (�4.4 to �0.8)

Stavudine

130

69 (53.1)

�0.11 (�5.8 to 5.6)

2.9 (�6.1 to 11.9)

0.12 (�1.4 to 1.6)

Didanosine

137

27 (19.7)

0.70 (�8.5 to 9.9)

�3.6 (�17.1 to 9.9)

0.08 (�1.8 to 2.0)

Zalcitabine

141

6 (4.3)

�4.8 (�11.8 to 2.3)

b

�14.1 (�25.7 to �2.6)

b

1.8 (�0.13 to 3.7)

�1.3 (�3.1 to 0.5)

�0.17 (�1.3 to 1.0)

�0.39 (�1.4 to 0.62)

c

b

2.0 (0.42– 3.6)

Men: 0.66 (�0.94 to 2.3);
�0.26 (�1.9 to 1.4)
c
women: �6.4 (�10.3 to �2.5)

0.54 (�1.5 to 2.6)

Men: 0.70 (�0.34 to 1.7);
�1.0 (�2.7 to 0.7)
b
women: �3.4 (�6.8 to �0.03)

0.90 (�3.0 to 4.8)

NOTE. This table summarizes many adjusted models. Sample sizes vary from model to model, because each analysis includes only subject ﬁles that have complete covariate data and meet all inclusion criteria. A subject
was considered to be in the ART group or HAART group if they reported continuous ART or HAART use from the beginning of the interval through the end of the interval. A subject was considered to be ART or HAART
naive if the subject reported no ART or HAART use in the 12 months prior to entry into the Nutrition for Healthy Living Study and did not receive ART or HAART through the end of the interval. PI-based HAART was deﬁned
as �2 PIs or 1 PI and 2 NRTIs. Mixed HAART was deﬁned as �1 NRTI, 1 PI, and 1 NNRTI. NNRTI-based HAART was deﬁned as �1 NNRTI and 2 PIs. 3-NRTI HAART was deﬁned as �3 NNRTIs. ART, antiretroviral therapy;
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a

Models were adjusted for sex, age, CD4+ cell count baseline value, change in CD4+ cell count, viral load baseline value, change in viral load, energy intake !35 g/kg, and strength training. Bone mineral content models
were also adjusted for smoking, calcium intake less than the dietary reference intake value, and vitamin D intake less than the dietary reference intake value. Drug/sex interactions were tested for all drugs.
b
P � .05 by Student’s t test, x2 test, Fisher’s exact test, or Wilcoxon rank sum test, as appropriate.
c
P � .01 by Student’s t test, x2 test, Fisher’s exact test, or Wilcoxon rank sum test, as appropriate.

�1.4% to �2.3%) and extremities (coefﬁcient range, �1.1%
to �3.2%). In the HAART model, each year of age predicted
a more rapid decrease in trunk LM (mean decrease per year,
�0.05%; 95% CI, �0.09% to �0.006%; P p .03).
DISCUSSION
With the advent of new and effective antiretroviral therapies,
immune restoration and viral suppression are now possible in
HIV-infected adults in the United States. As a result, it has been
difﬁcult to determine which medication and host factors are
associated with the varying aspects of body composition alter
ations. Many previously reported analyses did not use contin
uous or objective measures of change, have been crosssectional, have not included HAART-naive persons for
comparison, did not look directly at the effects of CD4+ cell
counts or viral loads after adjustment, or did not consider such
behaviors as dietary intake and smoking [6, 7, 14, 22]. Although
case reports and initiation studies have implicated the intro
duction of HAART in rapidly inducing body-shape changes in
some people, it remains unclear whether these changes continue
to evolve with continuous HAART or antiretroviral therapy
use. We offer exploratory ﬁndings from a longitudinal exam
ination of regional body composition changes in a large cohort
of HAART or antiretroviral therapy–experienced and –naive
men and women, and we demonstrate ongoing changes in
individuals receiving stable therapies.
This analysis conﬁrms an average annual loss of extremity
fat in the cohort. DEXA cannot distinguish between upper and
lower trunk fat, nor can it distinguish between the visceral and
subcutaneous compartments of the abdomen, but total trunk
fat changes were not found. Most importantly, disease status
was associated with regional body changes, because a lower
baseline CD4+ cell count (P � .006) or a higher baseline viral
load (P � .03) predicted a greater loss of trunk and limb fat.
HAART use or its duration did not contribute to change. Of
interest, zidovudine but not stavudine was associated with loss
of limb and trunk fat. Because of the time frame in which data
were collected, we were unable to determine the effect of some
individual medications, including abacavir and the NNRTIs.
These ﬁndings agree with the current literature that suggests
lipoatrophy is the unique physical manifestation of HIV infec
tion, and they support the ﬁndings from our group and others
that disease status is involved [4, 6, 19, 23–25]. However, it
remains impossible to separate the individual effects of anti
retroviral therapy agents, because they are used in combination.
Changes in LM have been less well investigated in the
HAART era. An early report from our group found that, after
HAART initiation, weight increased, and LM did not [8], but
our later reports found greater LM in individuals receiving
HAART than in others [5]. The current longitudinal study
conﬁrms that ongoing improvement in CD4+ cell count was

concurrent with gains in extremity LM, perhaps because the
latter reﬂects improved health, nutrition, and mobility that may
occur with an improvement in CD4+ cell count.
It appears that both medication and modiﬁable lifestyle fac
tors altered bone health in our cohort. HAART use and PI use
remained associated with bone mineral loss, even after adjust
ment for the strong effects of numerous well-known osteopenia
cofactors. Other signiﬁcant risk factors included cigarette smok
ing and dietary practices. The literature has been conﬂicted
about the prevalence of predictors of BMC changes [12, 26–
29]. Our analysis supports the involvement of antiretroviral
therapy, as well as known risk factors, reinforcing the need for
additional longitudinal studies that account for diet, cigarette
smoking, and medications concurrently.
Although a cohort such as this does not allow us to examine
the changes induced by the introduction of HAART (as would
be possible in a randomized control trial), our data do assist
in understanding the real-world situation for many patients
who experience ongoing body changes over time while receiving
treatment. Though our numbers were small for some analyses,
statistical differences were apparent. These ﬁndings suggest the
importance of peak viral load and nadir CD4+ cell count on
the subsequent loss of fat, a concurrence in the improvements
in CD4+ cell count and LM, and the primary inﬂuences of
medications and traditional risk factors in bone deminerali
zation. Many details about HIV-associated body composition
alterations remain unanswered, but this work conﬁrms the
growing body of evidence that such changes are multifactorial.
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